MassBioEd

Kelly Pitt is the Vice President, Legal and Head of Compliance at Nuvation Bio Inc. She has over 14 years of experience in the pharmaceutical/biotech industry supporting oncology, rare disease, and specialty businesses. Prior to joining Nuvation Bio, Kelly held roles of increasing responsibility in legal and compliance at MorphoSys US (acquired by Novartis), Mirati Therapeutics, Sobi North America, Keryx Biopharmaceuticals, and EMD Serono. Kelly received her B.A. from Palm Beach Atlantic University and her J.D. from Nova Southeastern University. 

Erin Colgan has more than twenty years of finance and accounting experience, with more than ten years making strategic financial and operational decisions for public and private, small- and large-cap life sciences firms.  In 2024, Erin Colgan joined Flagship Pioneering as Senior Vice President of Finance, working within the central finance operations team with a focus on financial planning, accounting operations and procurement.

In her prior role at Sensei Biotherapeutics, Ms. Colgan was the CFO following a successful IPO in February 2021. She collaborated with Sensei leadership to manage investor and banking relations, while working closely with the Board on the Audit Committee and Compensation Committees.  Before Sensei she served as vice president of FP&A and commercial planning at Intarcia Therapeutics, running the annual budgeting process as the company prepared to launch a Type II diabetes product. At Vertex Pharmaceuticals, Ms. Colgan held numerous finance and accounting leadership roles. She served as Controller in U.K. operations, supporting the launch of the company’s global CF franchise. There she led the operations team in creating new entities in Europe, Australia, and South America. She also collaborated with senior leadership to oversee all G&A expenses, commercial expenses, inventory cost planning, and global revenue planning and commercial forecasting.

Ms. Colgan began her career in public accounting at PwC where she worked in both audit and business development. She holds a B.A. in accounting from the University of Massachusetts, Amherst.

Lora is the Vice President of Patient Advocacy, Engagement & Innovation at Cogent Biosciences. She has over 15 years of experience working in the rare disease biotech space and social services. Prior to joining Cogent, she held several roles of increasing leadership responsibility in the areas of Marketing, Patient Services, Operations, and Patient Advocacy at Sanofi Genzyme, Alnylam, Sobi, and Kiniksa Pharmaceuticals. She began her career with the Commonwealth of Massachusetts as a Social Worker providing case management and support for underserved families in the state. As a part of the Sanofi Talent Executive Program, she helped develop a Career Lattice vs. Ladder Summit and Mentorship Program. While at Sanofi Genzyme, she also received the Sanofi Champion of Customers Award, which is granted to the top 1% in the company globally.

Lora received her B.A. in Psychology from the University of Rochester and completed the Strategic Marketing Management Executive Education Program at the University of Chicago Booth School of Business. She is also a member of the Wampanoag Tribe of Aquinnah and is passionate about professional development, mentorship, diversity, and inclusion in biotech and life sciences.

Kristin P. Goppel is the Vice President, Program Management at Insight Medical Consulting. Kristin is focused on providing strategic consulting services to clients in both the medical device and pharmaceutical industries.  She leverages her technical engineering and project management background to support program development for novel and emerging technologies across various therapeutic areas, including early interactions with regulatory agencies, pre-clinical test program development, and clinical trial planning and execution. 

Most recently, Kristin held roles in strategic consulting and program management at Avania LLC, a global medtech CRO, and at Worcester Polytechnic Institute, leading strategic initiatives in life science and bioengineering.  Her prior technical experience spans from facilities engineering and bioreactor design (Genzyme), to process engineering (Anika Therapeutics), and R&D (Arthur D. Little, Procter & Gamble).  She serves as the Vice-Chair of the Board of Directors for the Massachusetts Biotechnology Education Foundation, a nonprofit organization committed to uniting employers, academia and government to deliver impactful life science education programs for those in secondary school and throughout a professional career.        

Kristin earned her B.S. in Chemical Engineering from Cornell University and is an active alumna.